CYP2B6*6 is associated with increased breast cancer risk

International Journal of Cancer

Volumn 134, Issue 2, 2014, Pages 426-430

  Justenhoven, Christina ^a   Pentimalli, Daniela ^a   Rabstein, Sylvia ^b   Harth, Volker ^b,c   Lotz, Anne ^b   Pesch, Beate ^b   Brüning, Thomas ^b   Dörk, Thilo ^d   Schürmann, Peter ^d   Bogdanova, Natalia ^d   Park Simon, Tjoung Won ^d   Couch, Fergus J ^e   Olson, Janet E ^e   Fasching, Peter A ^f,g   Beckmann, Matthias W ^g   Häberle, Lothar ^g   Ekici, Arif ^g   Hall, Per ^h   Czene, Kamilla ^h   Liu, Janjun ⁱ   Li, Jingmei ⁱ   Baisch, Christian ^j   Hamann, Ute ^k   Ko, Yon Dschun ^j   Brauch, Hiltrud ^a   more..

^a Bioscientia Center for Human Genetics   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ GENOME INSTITUTE OF SINGAPORE   (Singapore)

^j Johanniter Krankenhaus   (Germany)

^k GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

more..

Author keywords

breast cancer risk; CYP2B6; polymorphism; testosterone

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P 450 CYP2B6; CYTOCHROME P-450 CYP2B6; TESTOSTERONE; TUMOR MARKER; UNSPECIFIC MONOOXYGENASE;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GERMANY; HETEROZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; RISK ASSESSMENT; SEQUENCE ANALYSIS; SWEDEN; UNITED STATES; VALIDATION STUDY; AGED; BREAST CANCER RISK; BREAST TUMOR; COMPARATIVE STUDY; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MASS SPECTROMETRY; META ANALYSIS (TOPIC); MIDDLE AGED; POLYMORPHISM; PROGNOSIS; RISK FACTOR; VERY ELDERLY;

BREAST CANCER RISK; CYP2B6; POLYMORPHISM; TESTOSTERONE;

ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; META-ANALYSIS AS TOPIC; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84887457273     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28356     Document Type: Article

References (29)

1. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? J Clin Oncol 2006; 24: 1823-30. (Pubitemid 46638979)
2. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003; 95: 1218-26. (Pubitemid 37069552)
3. Onland-Moret NC, Kaaks R, Van Noord PA, et al. Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br J Cancer 2003; 88: 1394-9. (Pubitemid 36606421)
4. Poutanen M, Isomaa V, Peltoketo H, et al. Role of 17 beta-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis. J Steroid Biochem Mol Biol 1995; 55: 525-32. (Pubitemid 26019338)
5. Imaoka S, Yamada T, Hiroi T, et al. Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. Biochem Pharmacol 1996; 51: 1041-50.
6. Zanger UM, Schwab M,. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variations. Pharmacol Ther 2013; 138: 103-41.
7. El-Rayes BF, Ali S, Heilbrun LK, et al. Cytochrome p450 and glutathione transferase expression in human breast cancer. Clin Cancer Res 2003; 9: 1705-9. (Pubitemid 36554594)
8. Iscan M, Klaavuniemi T, Coban T, et al. The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue. Breast Cancer Res Treat 2001; 70: 47-54. (Pubitemid 33105102)
9. Tozlu S, Girault I, Vacher S, et al. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 2006; 13: 1109-20. (Pubitemid 46212566)
10. Lo R, Burgoon L, Macpherson L, et al. Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells. Biochim Biophys Acta 2010; 1799: 469-79.
11. Hofmann MH, Blievernicht JK, Klein K, et al. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6\6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 2008; 325: 284-92. (Pubitemid 351439175)
12. Lamba V, Lamba J, Yasuda K, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 2003; 307: 906-22. (Pubitemid 37494207)
13. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399-415. (Pubitemid 32656581)
14. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-93. (Pubitemid 47014426)
15. Lambrechts D, Truong T, Justenhoven C, et al. 11q13 is a susceptibility locus for hormone receptor positive breast cancer. Hum Mutat 2012; 33: 1123-32.
16. Ghoussaini M, Fletcher O, Michailidou K, et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 2012; 44: 312-18.
17. Justenhoven C,. Polymorphisms of phase I and phase II enzymes and breast cancer risk. Front Genet 2012; 3: 258.
18. Justenhoven C, Pierl CB, Haas S, et al. The CYP1B1-1358-GG genotype is associated with estrogen receptor-negative breast cancer. Breast Cancer Res Treat 2008; 111: 171-7.
19. Pesch B, Ko Y, Brauch H, et al. Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol 2005; 20: 699-711. (Pubitemid 41266867)
20. Schrauder M, Frank S, Strissel PL, et al. Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. J Cancer Res Clin Oncol 2008; 134: 873-82.
21. Dork T, Bendix R, Bremer M, et al. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res 2001; 61: 7608-15. (Pubitemid 32995055)
22. Wedren S, Lovmar L, Humphreys K, et al. Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res 2004; 6: R437-R449.
23. Olson JE, Ma CX, Pelleymounter LL, et al. A comprehensive examination of CYP19 variation and breast density. Cancer Epidemiol Biomarkers Prev 2007; 16: 623-5. (Pubitemid 46548672)
24. Turpeinen M, Zanger UM,. Cytochrome P450 2B6: function, genetics, and clinical relevance. Drug Metabol Drug Interact 2012; 27: 185-97.
25. Key TJ,. Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids 2011; 76: 812-15.
26. Kumagai J, Fujimura T, Takahashi S, et al. Cytochrome P450 2B6 is a growth-inhibitory and prognostic factor for prostate cancer. Prostate 2007; 67: 1029-37. (Pubitemid 46983333)
27. Kurosaki T, Suzuki M, Enomoto Y, et al. Polymorphism of cytochrome P450 2B6 and prostate cancer risk: a significant association in a Japanese population. Int J Urol 2009; 16: 364-8.
28. Yuan ZH, Liu Q, Zhang Y, et al. CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility. Ann Hematol 2011; 90: 293-9.
29. Zanger UM, Klein K, Saussele T, et al. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007; 8: 743-59. (Pubitemid 47288975)